Urgently needed: A funding mechanism to insulate cancer research from political whims

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Jonathan Mahler’s article in the Sept. 14 issue of The New York Times Magazine provided an excellent overview of the Trump administration’s assault on cancer research. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Paul W. Thurman, DBA
Professor of management and analytics, Joseph L. Mailman School of Public Health, Columbia University Medical Center, Columbia University
Table of Contents

YOU MAY BE INTERESTED IN

Curebound has announced eight grants for a total of $2 million in funding. The funding is made available through two new Curebound programs: Catalyst Grants, which support projects within early-stage life science companies that are seeking to take innovative discoveries to commercially approved products, and Equity Grants, which focus on overcoming disparities in cancer research and treatment in underserved populations.
Paul W. Thurman, DBA
Professor of management and analytics, Joseph L. Mailman School of Public Health, Columbia University Medical Center, Columbia University

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login